Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.64 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909374 | 0.90 | S1PR1 (0.66) | S1PR1FOLH1HDAC3HDAC1HDAC2 | |
| SCHEMBL9909344 | 0.84 | S1PR1 (0.66) | S1PR1 | |
| SCHEMBL16506178 | 0.82 | S1PR1 (0.78) | S1PR1FOLH1ADRB1ADRB3ADRB2 | |
| SCHEMBL16506665 | 0.82 | S1PR1 (0.77) | S1PR1FOLH1ADRB1ADRB3ADRB2 | |
| SCHEMBL9112973 | 0.81 | S1PR1 (0.56) | S1PR1FOLH1HDAC3HDAC1HDAC2 | |
| SCHEMBL16468792 | 0.81 | S1PR1 (0.73) | S1PR1FOLH1HDAC3HDAC1HDAC2 | |
| SCHEMBL15193299 | 0.80 | S1PR1 (0.69) | S1PR1ADRB1ADRB3ADRB2 | |
| SCHEMBL9110982 | 0.80 | S1PR1 (0.59) | S1PR1FOLH1ADRB1ADRB3ADRB2 | |
| SCHEMBL16719282 | 0.80 | S1PR1 (0.57) | S1PR1FOLH1FFAR1FFAR4LMNA | |
| SCHEMBL15193302 | 0.80 | S1PR1 (0.73) | S1PR1ADRB1ADRB3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142640-A1 | ALKYNE AND ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE-1 RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142640-A1 | ALKYNE AND ALKENE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE-1 RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885FOLH1 2662/4885HDAC3 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.